In 1986, the dominant component of NFT, hyperphosphorylated Tau, was purified from the brain tissue of an AD patient [27], helping to explain the mutation in the Tau gene and its critical role in the progression of AD [28], and establishing the Tau hypothesis. This evidence concerns the gene MAPT and Alzheimer disease.